Advancing the global public health agenda for NAFLD: a consensus statement

By J. Lazarus, H. Mark, Q. Anstee, J. Arab, R. Batterham, Laurent Castéra, H. Cortez‐Pinto, J. Crespo, K. Cusi, M. Dirac and 211 more. Nature reviews: Gastroenterology & hepatology, 2021

631 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/bb4083973295afa23af7db44de016d8022a79bbc

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. J. D. Yang

In Hepatology

1. J. D. Yang

Citations in the corpus

• Global incidence and prevalence of nonalcoholic fatty liver disease (2022, background): “This serves as a call to action for greater political will and resources directed toward combating metabolic risk factors for NAFLD, at a regional and global level.(64,65)”
• Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2022, neutral): “People with type 2 diabetes frequently have NAFLD and are at increased risk for progression to more severe stages of liver disease, including NASH, hepatic fibrosis and cirrhosis [290].”